-
Key Brands
-
Statistics
-
Revenue
-
Contribution
-
Analysis
| Brand | Therapeutic category |
|---|---|
|
Diprivan |
General anaesthetic |
|
Meticorten |
Corticosteroid |
|
Milk of Magnesia |
Antacids-antiflatulants |
|
Perfalgen |
Analgesic injectable |
|
Xylocaine |
Regional anaesthetic |
5
Products
Launched
Launched
(2021: 3)
Product
Recalls
Recalls
(2021: 1)
5
%
Average Staff
Turnover
Turnover
(2021: 14%)
Work-related
Facilities
Facilities
(2021: Nil)
135
Sales
Representatives
Representatives
(2021: 574)
250
Permanent
Employees
Employees
(June 2021: 768)
| Revenue |
2022 R’million |
2021 (CER) R’million |
Change % |
|---|---|---|---|
|
Commercial Pharmaceuticals |
|||
|
Regional Brands |
2 856 |
2 636 |
8 |
|
Sterile Focus Brands |
1 439 |
1 400 |
3 |
|
Total |
4 295 |
4 036 |
6 |
Note: Commercial Pharmaceuticals revenue is by customer geography.
Contribution to Group revenue (%)
- Rest of Group 89
- Americas 11
Revenue by segment (%)
- Regional Brands 66
- Sterile Focus Brands 34
- The Mexican pharmaceutical market grew 8% to EUR9,01 billion MAT June 2022, positively impacted by growth across the generic, ethical and OTC markets.
- Pharmaceutical sales across the total Spanish Latin America market grew 13,6% to EUR22,5 billion MAT June 2022.
Source: IQVIA – June 2022
MAT= Moving annual total
